Chicago, IL – May 21, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. PFE, The Coca-Cola Co. KO and The Walt Disney Co. DIS.
Here are highlights from Tuesday’s Analyst Blog:
The wide moat strategy involves investing in companies that not only lead their industries but are also strategically fortified to maintain dominance in the future. The business models of these companies possess durable competitive advantages that shield them from competitors. This strategy isn't just about short-term gains, but securing a portfolio of stocks that can weather economic storms and continue to deliver stable and predictable returns.
This investment strategy focuses on companies with unique strengths such as brand recognition, patent protection, proprietary technology, and network effects. These moats ensure long-term profitability and market leadership, making the companies resilient in volatile markets.
Here we recommend three Wide Moat stocks with a favorable Zacks Rank. These stocks have solid short-term price upside potential. The stocks are Pfizer Inc., The Coca-Cola Co. and The Walt Disney Co.. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Pfizer
Pfizer is one of the largest and most successful drugmakers in the field of oncology. Its position in oncology was strengthened with the addition of Seagen. This drug generated sales of $3.4 billion in 2024, up 38% on a pro forma basis.
PFE has committed significant resources toward the development of treatments in the fields of oncology, internal medicine, immunology and inflammation and vaccines. In 2024, PFE gained approval for some interesting new products like two gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix (fidanacogene elaparvovec).
PFE expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Continued growth in non-COVID sales and significant cost-reduction measures should drive profit growth.
Pfizer has an expected revenue and earnings growth rate of 0.6% and 1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.4% in the last 30 days.
Pfizer presently carries a forward P/E of 7.41X for the current-year, compared with 12.96X for the industry and 19.20X for the S&P 500. PFE currently carries a forward P/S of 2.08X for the current-year, compared with 3.15X for the industry and 2.99X for the S&P 500. It also carries a forward P/B of 1.43X for the current-year, compared with 4.66X for the industry and 3.52X for the S&P 500.
The short-term average price target of brokerage firms for the stock represents an increase of 23.7% from the last closing price of $23. The brokerage target price is currently in the range of $23-$33. This indicates a maximum upside of 43.5% and no downside.
Coca-Cola
Coca-Cola experiences positive business trends, as evidenced by its strong track record of beating expectations. KO has benefited from continued business momentum, aided by higher pricing across markets facing intense inflation and a favorable mix.
Coca-Cola's all-weather strategy, combining marketing, innovation, and revenue growth management, supports its vision of a total beverage company and is expected to drive revenue growth in 2025. KO has provided an optimistic view for 2025.
Coca-Cola has an expected revenue and earnings growth rate of 2.4% and 2.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has remained the same in the last 60 days. KO has a return on equity (ROE) of 45.5% compared with 14.1% for the industry and 16.92% for the S&P 500.
The short-term average price target of brokerage firms for the stock represents an increase of 11.1% from the last closing price of $71.93. The brokerage target price is currently in the range of $70-$86. This indicates a maximum upside of 19.6% and a downside of 2.7%.
Walt Disney
The Walt Disney reported steady second-quarter fiscal 2025 results wherein revenues and earnings increased year-over-year. Domestic Parks & Experiences saw growth at domestic parks, Disney Vacation Club and Disney Cruise Line, partially offset by the decline at international locations including Shanghai Disney Resort and Hong Kong Disneyland Resort.
In Entertainment, DIS expects double-digit percentage segment operating income growth in fiscal 2025. ESPN continues to reinforce its position as sports' dominant platform, with the second quarter delivering its most-watched primetime ever and 32% viewership growth in the key 18-49 demographic.
DIS has successfully transformed its streaming business from a loss-leader to a profitable growth engine. After reporting its first-ever Direct-to-Consumer (DTC) operating profit in FY2024, the momentum has accelerated in FY2025 with second-quarter DTC operating income reaching $336 million.
The Walt Disney has an expected revenue and earnings growth rate of 3.8% and 15.1%, respectively, for the current year (ending September 2025). The Zacks Consensus Estimate for current-year earnings has improved 4.6% in the last 30 days. At present, DIS carries a forward P/E of 19.83X for the current year, compared with 20.37X for the industry and 19.20X for the S&P 500.
The short-term average price target of brokerage firms for the stock represents an increase of 10.9% from the last closing price of $112.66. The brokerage target price is currently in the range of $100-$148. This indicates a maximum upside of 31.4% and a downside of 11.2%.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CocaCola Company (The) (KO) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
The Walt Disney Company (DIS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
